Merz Pharma Withdraws $22/Share Bid for Obagi Medical (OMPI)

April 8, 2013 8:42 AM EDT Send to a Friend
Merz Pharma Group has withdrawn its non-binding proposal to acquire all of the outstanding common stock of Obagi Medical Products, Inc. (Nasdaq: OMPI) ("Obagi") for $22 per share in cash. The decision to withdraw the proposal follows the recent announcement that Valeant Pharmaceuticals International, Inc. (NYSE: VRX) increased its offer to acquire Obagi from $19.75 to $24.00 per share in cash, pursuant to an amendment to the Valeant and Obagi Agreement and Plan of Merger, dated March 19, 2013.

"Obagi was an opportunity worth pursuing given its complementary fit with Merz's portfolio of injectables," said Merz CEO Philip Burchard. "However, Merz is a disciplined buyer and at this level the economics of such a transaction do not meet our requirements. We look forward to exploring other acquisition opportunities that fit our strategy. In addition, we will build on Merz's strong position in the markets we serve and continue to invest in our own R&D."


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Hot Corp. News, Mergers and Acquisitions

Add Your Comment